查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
电子临床结果评估解决方案的全球市场：2023-2030
市场调查报告书
商品编码
1279675

电子临床结果评估解决方案的全球市场：2023-2030

Global Electronic Clinical Outcome Assessment Solutions Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 194 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

电子临床结果评估解决方案的全球市场预计到 2022 年将达到 12.39 亿美元，到 2030 年将达到 42.498 亿美元，并实现利润丰厚的增长。 预计在预测期内（2023-2030 年）复合年增长率将达到 17.3%。

电子临床结果评估解决方案是医生快速有效地进行随机临床研究的工具。 这些 eCOA 系统从多个位置持续收集数据，以帮助改善患者安全和招募流程。 随着早期试验获得更多优先权，最终用户使用这些系统的频率更高。

电子临床结果评估解决方案市场包括许可的、基于云的和网络託管的产品，增加了这些产品的市场份额。 患者报告评估、临床医生报告评估、观察者报告评估和绩效评估等方法的市场份额正在增长，因为它们属于电子临床结果评估解决方案的范围。

市场动态

主要製药和生物製药公司越来越多地将临床试验研究外包，这推动了电子临床结果评估解决方案市场的增长。

慢性病患病率上升、新治疗方式的开发、新产品的发布以及电子平台等技术改进正在促进全球电子临床结果评估解决方案市场的增长。

为了更好地了解治疗效果，监管机构强调了对患者健康状况进行更广泛研究的重要性。 因此，越来越多地使用临床结果评估 (COA) 来评估各种慢性疾病的治疗效果。 在某些情况下，它还有助于新药的批准。

此外，市场将随着许多新服务的引入而扩大。 例如，2021 年 6 月，Signant Health 宣布了一项新的加速计划，在不影响所提供临床数据质量的情况下，将研究准备时间缩短 50% 以上，从而导致市场扩张显着增加。

不断增加的研发支出和技术进步为製造商创造了有利可图的机会

电子临床结果评估解决方案在许多临床试验中越来越被广泛接受，因此存在巨大的市场机会。 对电子临床结果评估解决方案中使用的方法和产品的高需求将为製造商提供有利可图的增长选择。

随着主要参与者大力投资于研发能力以改进其尖端技术，新兴市场有机会。 许多公司正在开发尖端技术来治疗多种疾病，并通过临床试验评估最佳治疗方法。

高昂的引进成本阻碍了市场增长

中型製药公司和临床试验发起人越来越担心构建 eCOA 解决方案的初始成本高。 电子数据收集可能需要大量的初始成本（例如，购买软件平板电脑或计算机、设备成本、与软件开发商签订合同、手机上网等）。

COVID-19 影响分析

除了 COVID 之前、COVID 和 COVID 之后的情景外，COVID-19 的分析还包括价格动态（与 COVID 情景相比，大流行期间的价格变化）、供需范围（交易限制、封锁）。 ，由于后续问题引起的供需变化），政府举措（政府机构的市场，行业和部门振兴努力），以及製造商的战略举措。

俄乌衝突影响分析

由于该地区的主要市场参与者数量较少，估计俄罗斯-乌克兰衝突对全球电子临床结果评估解决方案市场的影响较小。 然而，原材料进出口的影响预计在预测期内对全球电子临床结果评估解决方案市场的增长影响不大。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按投放方式分类的摘要
  • 方法片段
  • 最终用户的片段
  • 区域摘要

第四章市场动态

  • 影响因素
    • 主持人
      • 主要製药公司和生物製药公司增加了临床试验研究的外包
      • 对基于云的服务的需求不断增长
    • 约束因素
      • 引进成本高
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 法律法规分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按交付方式

  • 网络託管
  • 基于云
  • 许可行业

第 8 章方法

  • 患者报告的评估
  • 临床医生报告的评估
  • 观察员报告的评估
  • 绩效/评估

第 9 章最终用户

  • 製药和生物製药公司
  • 门诊中心
  • 签约研发组织
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 中东和非洲
    • 各地区的主要动态

第11章竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第12章公司简介

  • 艾昆纬控股公司
    • 公司简介
    • 交付模式组合和说明
    • 财务摘要
    • 主要发展状况
  • Oracle Corporation
  • Dassault Systems SE
  • Parexel International Corporation
  • IBM Corporation
  • Signant Health
  • Clario
  • eClinical Solutions LLC
  • Castor
  • Anju Software

第13章 附录

简介目录
Product Code: HCIT4784

Market Overview

The global electronic clinical outcome assessment solutions market reached US$ 1,239.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,249.8 million by 2030. The market is expected to exhibit a CAGR of 17.3% during the forecast period (2023-2030).

Clinical Outcome Assessment (eCOA) Solutions are tools that let doctors conduct randomized clinical studies quickly and effectively. These eCOA systems help collect data consistently from numerous locations to improve the safety of patients and the hiring process. End users utilize these systems more often because early-phase testing is being prioritized more.

The electronic clinical outcome assessment solutions market includes licensed, cloud-based, and web-hosted delivery methods, which has increased the market share for these products. The approaches such as patient-reported outcome, clinician-reported outcome, observer-reported outcome, and performance outcome fall under the purview of electronic clinical outcome assessment solutions, which has increased its market share.

Market Dynamics

Increasing Externalization of Clinical Trial Studies by Large Pharmaceutical And Biopharmaceutical Companies Drives the Growth of the Electronic Clinical Outcome Assessment Solutions Market.

The prevalence of chronic illnesses is increasing, new treatment methods are being developed, new products are being released, and technology improvements such as electronic platforms are all contributing to the growth of the global electronic clinical outcome assessment solutions market.

In order to more accurately characterize therapeutic gain, regulatory agencies have stressed the significance of examining broader elements of patient well-being. Clinical outcome assessments (COAs) are therefore being used more frequently to evaluate the effectiveness of treatments for different chronic conditions. In certain instances, they have even contributed to the approval of new drugs.

The market will also expand as a result of the introduction of numerous new services. For instance, in June 2021, Signant Health unveiled a new acceleration program that reduces study setup time by 50 percent or more without compromising the caliber of clinical data delivered, leading to significant market expansion.

Growing R&D Expenditure and Technological Advancements Creates Lucrative Opportunities for Manufacturers.

There is a sizable market opportunity for electronic clinical outcome assessment solutions as it is becoming more widely acceptable in numerous clinical trials. Manufacturers are going to have profitable choices for growth as demand for approaches and products utilized for electronic clinical outcome assessment solutions will be high.

Due to key players' significant investments in research and development capabilities for cutting-edge technical improvements, there is a developing market opportunity. Numerous businesses are creating cutting-edge technologies to treat several conditions, and evaluate the best treatment options via clinical trials.

The High Cost of Implementation Will Hamper the Market Growth.

Concern over the initial high cost of creating an eCOA solution is growing among mid-sized pharmaceutical producers and clinical trial sponsors. Electronic data collection may need a substantial initial financial outlay (for instance, to purchase tablets or computers with software, incur equipment costs, engage software developers, or use cellular internet).

COVID-19 Impact Analysis

The COVID-19 analysis includes the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to pricing dynamics (including pricing change during and after the pandemic evaluating it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply due to trading restrictions, lockdown, and afterward issues), government initiatives (initiatives to reactivate a market, industry, or sector by government bodies), and manufacturers strategic initiatives.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global electronic clinical outcome assessment solutions market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global electronic clinical outcome assessment solutions market growth over the forecast period.

Segment Analysis

The global electronic clinical outcome assessment solutions market is segmented based on delivery mode, approach, end-user, and region.

Patient Reported Outcome From Approach Segment Accounts for 46.7% of Electronic Clinical Outcome Assessment Solutions Market Share Owing to Rising Technological Advancements.

The health state of a patient is evaluated using patient-reported outcome measures (PROMs) at a certain period. The PROMs tools can be used to treat a problem while it is being treated or while the patient is unwell. The effectiveness of an intervention can occasionally be assessed using pre- and post-event PROMs.

In order to receive high-quality clinical care, patients must be able to describe their symptoms, feelings, and any side effects from any prescribed medications. The pharmaceutical business understood how critical it was to take patient-reported outcomes (PROs) and biomarkers of health improvement into account.

When medical service research started emphasizing enhancing patients' quality of life while undergoing optimal medical therapy, the distinction between medical results and treatment outcomes became more distinct. Consequently, the demand for identifiable, reliable, and valid patient-reported measures (PROMs) increased.

Geographical Analysis

North America Accounted for Approximately 33.9% of the Market Share Owing to the Strong Presence of Major Players and Increasing Research and Development.

Manufacturers have chances to expand their operations in this region because of the rising demand for electronic clinical outcome assessment solutions for various disorders in North America. This region has many producers and suppliers, and its rapid economic development has raised industrial production of electronic clinical outcome assessment solutions products, which has increased the demand.

The marketplace for electronic clinical outcome assessment solutions is anticipated to grow quickly as a result of an increase in clinical trials across the continent. As demand for medicinal research increases, clinical trials are expanding more and more in the US and Canada. Clinicians around the area rely on cutting-edge technologies for data management. Clinicians advise using eCOA options for clinical trial planning because to the necessity of their accessibility.

Competitive Landscape

The major global players in the electronic clinical outcome assessment solutions market include: IQVIA Holdings Inc, Dassault Systems SE, Oracle Corporation, Parexel International Corporation, Signant Health, IBM Corporation, Clario, Castor, eClinical Solutions LLC and Anju Software among others.

Why Purchase the Report?

  • To visualize the global electronic clinical outcome assessment solutions market segmentation based on delivery mode, approach, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of electronic clinical outcome assessment solutions market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global electronic clinical outcome assessment solutions market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Delivery Mode
  • 3.2. Snippet by Approach
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 4.1.1.2. Growing demand for cloud based services
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of implementation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Delivery Mode

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 7.1.2. Market Attractiveness Index, By Delivery Mode
  • 7.2. Web Hosted *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Cloud-Based
  • 7.4. Licensed Industries

8. By Approach

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Patient-reported outcome *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinician-reported outcome
  • 8.4. Observer-reported outcome
  • 8.5. Performance outcome

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Pharmaceutical & Biopharmaceutical Companies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Care Center
  • 9.4. Contract Research Organizations
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. IQVIA Holdings Inc *
    • 12.1.1. Company Overview
    • 12.1.2. Delivery Mode Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Oracle Corporation
  • 12.3. Dassault Systems SE
  • 12.4. Parexel International Corporation
  • 12.5. IBM Corporation
  • 12.6. Signant Health
  • 12.7. Clario
  • 12.8. eClinical Solutions LLC
  • 12.9. Castor
  • 12.10. Anju Software

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us